A clinical screening program for topical chemotherapeutic drugs in psoriasis.
In this national, multicenter cooperative study, a standardized drug screening program was designed and evaluated to test the clinical effectiveness of 30 topically applied chemotherapeutic drugs to psoriasis. Appropriate concentrations and vehicles for topical administration were selected with regard to clinical testing consisted of a double-blind application of test agents to psoriatic plaques under occlusion daily for up to nine days. Drugs known to be topically active in psoriasis, eg, thiotepa, fluorouracil, and betamethasone valerate, were easily detected in the clinical protocol, confirming the validity of this topical drug screening program. Seven drugs produced substantial clinical improvement with evidence of clearing; nine drugs produced slight improvement; 14 drugs had no effect. No systemic toxid reactions occurred. This screen should be useful to test other potential antipsoriatic drugs and to evaluate potential animal model screens for their predictive values with the same drugs.
D000328:Adult; D000818:Animals; D002986:Clinical Trials as Topic; D003513:Cycloheximide / Q000494:pharmacology; D003879:Dermatologic Agents / Q000494:pharmacology*; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D004640:Emetine / Q000494:pharmacology; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D008935:Mitoguazone / Q000494:pharmacology; D011565:Psoriasis / Q000188:drug therapy*; D011739:Pyrimethamine / Q000494:pharmacology; D011817:Rabbits; D012867:Skin / Q000187:drug effects; D013852:Thiotepa / Q000494:pharmacology
D003879:Dermatologic Agents; D013852:Thiotepa; D003513:Cycloheximide; D008935:Mitoguazone; D005472:Fluorouracil; D004640:Emetine; D011739:Pyrimethamine